[junkie-button url=”https://infomeddnews.com” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
The company reports the Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system for the treatment of bladder and bowel dysfunction. It is currently approved for sale in Europe, Canada and Australia.
The NUU publication includes three articles which describe the characteristics of the Axonics system and summarize the clinical results from a multi-center European clinical trial:
- “The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience” (Elterman, 2018), describes the Axonics system and implant technique
- “Three-month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder” (Blok et al., 2018), reports the 3-month safety and efficacy results of the RELAX-OAB study conducted in 51 patients suffering from Overactive Bladder
- “Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder” (Blok et al., 2018), reports the 3-month RELAX-OAB data on patient programming settings and charging experience
The publication of this special edition by NUU is reflective of the expanding interest for a miniaturized, rechargeable implant dedicated to SNM, as well as to the growing amount of clinical evidence supporting the use of the Axonics r-SNM System.
Last month, Axonics announced the first patient implants in the ARTISAN-SNM pivotal study were performed. This study is being conducted under an Investigational Device Exemption granted by the U.S. Food & Drug Administration and is designed to gain FDA Premarket Approval in the United States.